Ymke Appels stood before a room of cardiologists and oncologists in Rotterdam, her voice steady as she shared a finding that could change how cancer patients are cared for: heart-protecting drugs aren’t just preserving lives—they’re keeping hearts strong during grueling cancer treatments. At the ESC Cardio-Oncology 2026 conference, researchers from Erasmus University Medical Center unveiled a sweeping meta-analysis showing that common heart failure medications can shield the hearts of cancer patients from the damaging side effects of chemotherapy and other anticancer therapies. With over half a million cancer survivors living with cardiovascular complications worldwide, this intersection of cardiology and oncology—cardio-oncology—has become a critical frontier in modern medicine.
The team analyzed 49 studies involving 6,998 patients, focusing on how well certain heart failure drugs prevented cardiac decline in those undergoing cancer treatment. The results were clear: therapies like RAAS inhibitors and beta-blockers, long staples in managing heart failure, significantly preserved heart function. Left ventricular ejection fraction (LVEF), a key measure of how well the heart pumps blood, improved by 2.88% with RAAS inhibitors alone and by 2.98% when combined with beta-blockers—statistically significant gains that could mean the difference between continuing life-saving cancer therapy or halting it due to heart damage. Even global longitudinal strain, a more sensitive marker of early heart muscle dysfunction, showed improvement across treatment groups.
The data also hinted at promise beyond the standard toolkit. Mineralocorticoid receptor antagonists boosted LVEF by 4.68%, though based on just two studies, while sodium-glucose cotransporter-2 (SGLT2) inhibitors—a newer class of heart failure drugs—showed a 3.20% improvement in the single available study. Statins, typically used to lower cholesterol, also demonstrated a 2.49% increase in LVEF, suggesting broader cardiovascular protection. Yet, as principal investigator Dr. Wouter Meijers emphasized, the limited number of studies on these newer agents underscores an urgent need for more robust clinical trials.
What makes this research so impactful is its real-world relevance. Cancer treatments like anthracyclines and trastuzumab are known to weaken the heart, sometimes forcing doctors to pause or stop therapy—jeopardizing survival. By proactively using these cardioprotective drugs, clinicians may now have a way to keep both the heart and the cancer treatment on track. As cardio-oncology evolves from a niche specialty to a standard of care, these findings offer a roadmap. The future lies not just in treating two diseases at once, but in preventing one while fighting the other.